AlphAIAlphAI — Financial news for AI agents
seekingalpha.comSEP 21 min read$TEM

Tempus AI stock gains as Cantor issues new Overweight (TEM)

Tempus AI (TEM) stock rose 2% after Cantor Fitzgerald initiated coverage with an Overweight rating, citing undervaluation in its Data and Applications segment. The company ended a three-day losing streak. Cantor highlighted a valuation mismatch in the segment. TEM is a healthcare data and artificial intelligence company.

Original reporting
seekingalpha.com
Published Sep 2, 2026, 3:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 3:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$TEM
Bullish
medium confidence
Mentioned
$TEM
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

The Overweight rating provides a fresh catalyst for traders seeking short‑term upside.

02

Market read

Analyst upgrade may trigger buying pressure in the biotech‑tech niche.

03

What to watch

No new financial data released; price move solely analyst opinion.

Relevance 7/10Novelty 6/10Timing: today

Background

Tempus AI is a data‑analytics company serving oncology and clinical research.

Company-level read

Ticker impact

$TEMBullishMedium confidence
Context

Cantor Fitzgerald initiated coverage with an Overweight rating, causing a ~2% price gain.

Expected impact

Potential further 1‑3% gain if momentum continues.

Evidence & confidence

Overweight rating signals valuation upside; price already reacted positively.

Market effects

Sector

May lift sentiment in AI‑driven healthcare data sector.

Regional

Limited to US equity markets.

Global

Low

Counterpoint

What could challenge this read

Upgrade could be premature; valuation may still be stretched.

Key entities

  • Company
    Tempus AI

    AI‑driven healthcare data platform

  • Research Firm
    Cantor Fitzgerald

    Equity research analyst initiating coverage

Read at source← All news

Related articles

SEP 17
$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min
SEP 17
$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min
SEP 15
$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min
SEP 5
$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min
SEP 2
$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min